Research programme: ocular gene therapies: Otsuka Pharmaceutical/Shape Therapeutics
Alternative Names: Research programme: AAV gene therapies: Otsuka Pharmaceutical/Shape TherapeuticsLatest Information Update: 03 Oct 2023
At a glance
- Originator Otsuka Pharmaceutical; Shape Therapeutics
- Developer Otsuka Pharmaceutical
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Eye disorders